

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6796088

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GRAHAM BEATON	02/22/2016
FABIO C. TUCCI	02/22/2016
SATHEESH B. RAVULA	02/22/2016
STANTON F. MCHARDY	02/23/2016
FRANCISCO XAVIER RUIZ III	02/23/2016
AMBROSIO LOPEZ JR.	02/22/2016
BISMARCK CAMPOS	02/22/2016
HUA-YU LEO WANG	02/22/2016
RECEIVING PARTY DATA	
Name:	CURTANA PHARMACEUTICALS, INC.
Street Address:	1624 HEADWAY CIRCLE
Internal Address:	SUITE 100
City:	AUSTIN
State/Country:	TEXAS
Postal Code:	78754
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17367099
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8583502300
Email:	knelson@wsgr.com, patentdocket@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	44903-704.302
NAME OF SUBMITTER:	KATE NELSON

SIGNATURE:	/Kate Nelson/
DATE SIGNED:	07/02/2021
Total Attachments: 8 source=Curtana 44903-704.302 Assignment#page1.tif source=Curtana 44903-704.302 Assignment#page2.tif source=Curtana 44903-704.302 Assignment#page3.tif source=Curtana 44903-704.302 Assignment#page4.tif source=Curtana 44903-704.302 Assignment#page5.tif source=Curtana 44903-704.302 Assignment#page6.tif source=Curtana 44903-704.302 Assignment#page7.tif source=Curtana 44903-704.302 Assignment#page8.tif	

PATENT ASSIGNMENT

Docket Number: 44903-704.601

WHEREAS, the undersigned:

BEATON, Graham
18858 Bernardo Trails Drive
San Diego, CA 92128

TUCCI, Fabio C.
1329 Sutter Street
San Diego, CA 92103

RAVULA, Satheesh B.
15909 Sinclair Street
San Diego, CA 92127

(hereinafter "Inventor(s)"), has/have contributed to the invention of certain new and useful improvements in:

INHIBITION OF OLIG2 ACTIVITY

for which a PCT application claiming the benefit of U.S. Provisional Application No(s). 62/126,382, will be filed on or before February 27, 2016, in the U.S. Receiving Office of the Patent Cooperation Treaty (hereinafter "Application"), the subject matter of which the Inventor(s) has/have reviewed and understood.

WHEREAS, CURTANA PHARMACEUTICALS, INC., a corporation of the State of Delaware, having a place of business at 1624 Headway Circle, Suite 100, Austin, TX 78754, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:


1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions and Applications, including the right to claim priority to said Inventions and said Applications; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application; and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).
2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

PATENT ASSIGNMENT


Docket Number. 44903-704 601

IN WITNESS WHEREOF, said inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:


Date: 2/22/2016


Graham BEATON

Date: 2/22/2016



Fabio C. TUCCI

Date: 2/22/2016


Satheesh B. RAYULA

RECEIVED AND AGREED TO BY ASSIGNEE: CURTANA PHARMACEUTICALS, INC.

Date: 2/22/16

Signature: 
Name: Gregory STEIN, MD, MBA
Title: President and Chief Executive Officer

PATENT ASSIGNMENT

Docket Number: 44903-704.601

WHEREAS, the undersigned:

MCHARDY, Stanton F.
31 Bennitt Road
Waring, TX 78074

RUIZ, Francisco Xavier, III
1805 Jessie Ann Court
Conroe, TX 77304

LOPEZ, Ambrosio, JR.
7803 S New Braunfels
Apt# 2208
San Antonio, TX 78235

CAMPOS, Bismarck
7403 Tranquillo Way
San Antonio, TX 78266

WANG, Hua-Yu Leo
5511 Pecan Springs Road
Apt# 3103
San Antonio, TX 78249

(hereinafter "Inventor(s))," has/have contributed to the invention of certain new and useful improvements in:

INHIBITION OF OLIG2 ACTIVITY

for which a PCT application claiming the benefit of U.S. Provisional Application No(s). 62/126,382, will be filed on or before February 27, 2016, in the U.S. Receiving Office of the Patent Cooperation Treaty (hereinafter "Application"), the subject matter of which the Inventor(s) has/have reviewed and understood.

WHEREAS, CURTANA PHARMACEUTICALS, INC., a corporation of the State of Delaware, having a place of business at 1624 Headway Circle, Suite 100, Austin, TX 78754, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions and Applications, including the right to claim priority to said Inventions and said Applications; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application; and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

PATENT ASSIGNMENT

Docket Number: 44903-704.601


6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: 2/23/16 
Stanton F. MCHARDY


Date: 07/23/16 
Francisco Xavier RUIZ III

Date: 02/22/16 
Ambrosio LOPEZ JR.

Date: 02/22/16 
Bismarck CAMPOS

Date: 02/22/16 
Hua-Yu Leo WANG

RECEIVED AND AGREED TO BY ASSIGNEE: CURTANA PHARMACEUTICALS, INC.

Date: 2/25/16 Signature: 
Name: Gregory STEIN, MD, MBA
Title: President and Chief Executive Officer

WHEREAS, the undersigned:

BEATON, Graham	TUCCI, Fabio C.	RAVULA, Satheesh B.
18858 Bernardo Trails Drive	1329 Sutter Street	15909 Sinclair Street
San Diego, CA 92128	San Diego, CA 92103	San Diego, CA 92127

(hereinafter "Inventor(s)),) has/have contributed to the invention of certain new and useful improvements in:

INHIBITION OF OLIG2 ACTIVITY

for which a PCT application claiming the benefit of U.S. Provisional Application No(s). 62/126,382, will be filed on or before February 27, 2016, in the U.S. Receiving Office of the Patent Cooperation Treaty (hereinafter "Application"), the subject matter of which the Inventor(s) has/have reviewed and understood.

WHEREAS, CURTANA PHARMACEUTICALS, INC., a corporation of the State of Delaware, having a place of business at 1624 Headway Circle, Suite 100, Austin, TX 78754, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions and Applications, including the right to claim priority to said Inventions and said Applications; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application; and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).
2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

PATENT ASSIGNMENT

Docket Number: 44903-704.601

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____
Graham BEATON

Date: _____
Fabio C. TUCCI

Date: _____
Satheesh B. RAVULA

RECEIVED AND AGREED TO BY ASSIGNEE: CURTANA PHARMACEUTICALS, INC.

Date: _____ Signature: _____
Name: Gregory STEIN, MD, MBA
Title: President and Chief Executive Officer

WHEREAS, the undersigned:

MCHARDY, Stanton F.
31 Bennett Road
Waring, TX 78074

RUIZ, Francisco Xavier, III
1805 Jessie Ann Court
Conroe, TX 77304

LOPEZ, Ambrosio, JR.
7803 S New Braunfels
Apt# 2208
San Antonio, TX 78235

CAMPOS, Bismarck
7403 Tranquillo Way
San Antonio, TX 78266

WANG, Hua-Yu Leo
5511 Pecan Springs Road
Apt# 3103
San Antonio, TX 78249

(hereinafter "Inventor(s)"), has/have contributed to the invention of certain new and useful improvements in:

INHIBITION OF OLIG2 ACTIVITY

for which a PCT application claiming the benefit of U.S. Provisional Application No(s). 62/126,382, will be filed on or before February 27, 2016, in the U.S. Receiving Office of the Patent Cooperation Treaty (hereinafter "Application"), the subject matter of which the Inventor(s) has/have reviewed and understood.

WHEREAS, CURTANA PHARMACEUTICALS, INC., a corporation of the State of Delaware, having a place of business at 1624 Headway Circle, Suite 100, Austin, TX 78754, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions and Applications, including the right to claim priority to said Inventions and said Applications; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application; and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).
2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

PATENT ASSIGNMENT

Docket Number: 44903-704.601

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____
Stanton F. MCHARDY

Date: _____
Francisco Xavier RUIZ III

Date: _____
Ambrosio LOPEZ JR.

Date: _____
Bismarck CAMPOS

Date: _____
Hua-Yu Leo WANG

RECEIVED AND AGREED TO BY ASSIGNEE: CURTANA PHARMACEUTICALS, INC.

Date: _____ Signature: _____
Name: Gregory STEIN, MD, MBA
Title: President and Chief Executive Officer